Enicepatide Dosage, half-life & reference guide

Also known as CT-388 · CT388 · RO7795068

Reviewed 1 studyEvidence: ModeratePublished by PepVault

A weekly GLP-1 and GIP dual agonist from Roche, the same two receptors as tirzepatide, built to keep the receptors responsive by avoiding one of their shut-off signals. In its 48-week obesity phase 2 trial, the top 24 mg dose took off about 22.5% more weight than placebo, and the curve had not flattened.

Studied range
4–24 mgstarting dose 2 mg
How often
Weekly
Half-life
~5.5 days
Evidence
●●● Moderate
Route
SubQ injection

Studied in research — not a recommendation.

Enicepatide dose guide

How it works.

Once-weekly peptide that switches on both the GLP-1 and the GIP receptors, tirzepatide's pair, with a twist: it is built to trigger the receptors' main signal while barely recruiting beta-arrestin, the protein that pulls receptors inside the cell. The idea is that receptors stay on the surface and keep responding, so the effect lasts. Its half-life in people is about 5 to 6 days. Developed by Carmot Therapeutics and now Roche, in phase 3 since March 2026.

Commonly reported: In trials, GI side effects, mostly mild to moderate, during the step-ups. It is in phase 3 and not approved anywhere.

Half-life & active level

The half-life of Enicepatide is ~5.5 days (measured in people: mean 123–139 hours after single doses; phase 1, Chakravarthy 2026).

Here's how a typical Enicepatide schedule accumulates over four weeks (one-compartment estimate).

An estimate from the half-life above, not a measurement. See your own curve build live in the half-life calculator.

A smiling woman in a dark training top in her kitchen, holding a glass of water

Model. Individual results vary.

PepVault for iPhone

Track enicepatide in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Where Enicepatide works.

A body with Appetite & metabolism lit
  • Appetite & metabolism

    In people. At 48 weeks that group lost about 22.5% more weight than placebo, and nearly half lost at least 20% of their weight.

An area lights for what a peptide is used for and what people report, with the evidence beside it. It isn’t a promise that it works there.

Week by week.

What to expect in the first 8 weeks

Onset
Days–2 weeks
Peak effect
48 weeks (phase 2 endpoint, no plateau)
Duration
Ongoing
  1. Day 1–28 · 2 mgRCT

    Two milligrams, the first step

    You're on 2 mg, where the higher-dose groups in the phase 2 obesity trial began. Commonly reported: appetite dropping in the first days. In its trials, GI side effects were mostly mild to moderate and came with the step-ups.

    The science

    CT388-103 (NCT06525935; 469 adults with obesity or overweight without diabetes, 34 US sites): the 12, 16 and 24 mg groups started at 2 mg and stepped up through 4, 8, 12, 16 and 20 mg; the 4 and 8 mg groups started at 4 mg; all reached their top dose within 27 weeks, with delayed steps allowed for tolerability (Roche ADA 2026 poster). Most GI events were mild to moderate (Roche, Jan-27-2026).

    Sources
    • Roche (phase 2 obesity release) (2026)
    • Lingvay et al. (ADA poster) (2026)

    Updated Nov 2026

  2. Day 29–112 · 8 mgRCT

    Through the middle steps

    You're at 8 mg, one of the doses the phase 2 trial also tested as a final dose. Commonly reported: a few queasy days after each step, then steadier appetite control. A slower step was allowed in the trial when side effects needed time to settle.

    The science

    CT388-103 tested final doses of 4, 8, 12, 16 and 24 mg (about 78 people each) against placebo, with a clear dose response for weight (Roche, Jan-27-2026; ADA 2026 poster). Delayed titration was allowed weekly from week 8 for the three highest-dose groups.

    Sources
    • Roche (phase 2 obesity release) (2026)
    • Lingvay et al. (ADA poster) (2026)

    Updated Nov 2026

  3. Any dayRCT

    What Enicepatide is built on

    A phase 1 trial with a published paper, and two 48-week phase 2 trials, one in obesity and one in type 2 diabetes, reported by Roche. Phase 3 began in March 2026. It is not approved anywhere.

    The science

    Discovery and phase 1 (Chakravarthy 2026, Mol Metab; NCT04838405, sponsor Carmot): cAMP-biased at both receptors with minimal internalisation; weight loss in mice and monkeys; in people, single doses of 0.5 to 7.5 mg and four weekly doses of 5 to 12 mg, half-life 123 to 139 h, −4.7% to −8.0% at day 29 vs −0.5% on placebo. Phase 2: CT388-103 (obesity) and CT-388-104 (diabetes). Phase 3: ENITH-1 (NCT07351045, ~2,000, three dosing regimens) and ENITH-2 (NCT07351058), sponsor Hoffmann-La Roche.

    Sources
    • Chakravarthy et al. (2026)
    • Roche (phase 2 obesity release) (2026)
    • Roche (phase 2 diabetes release) (2026)

    Updated Nov 2026

  4. With BPC-157Community

    Why people add BPC-157 to a GLP-1

    GI side effects come mostly with the step-ups, and BPC-157, first studied as a stomach-protecting peptide, is added to ease them. Commonly reported: smoother step-ups. No trial has tested the pair.

    The science

    BPC-157's early research was on gastric protection in animal studies (Sikiric 2018 review). No trial has tested it alongside enicepatide or any GLP-1 drug; the pairing comes from community reports.

    Sources
    • Sikiric et al. (2018)

    Updated Nov 2026

After week 8

  1. Day 85–336RCT

    With type 2 diabetes

    In a 48-week trial in type 2 diabetes, the 24 mg dose lowered HbA1c by 2.65 points and weight by about 15.5%. Nine in ten on that dose reached an HbA1c of 6.5% or lower, and few stopped for side effects.

    The science

    CT-388-104 (NCT06628362; 447 adults with type 2 diabetes and overweight or obesity): at 24 mg, HbA1c −2.65% from 8.1% (−4.13% when baseline was above 8.5%); 90% reached ≤6.5% and 62% below 5.7%; weight −15.5% with no plateau; stopping for side effects 2.0% on enicepatide vs 0.0% on placebo (Roche, Sep-22-2026; topline).

    Sources
    • Roche (phase 2 diabetes release) (2026)

    Updated Nov 2026

  2. Day 113–336 · 24 mgRCT

    The top dose tested

    You're at 24 mg, the highest dose in phase 2. At 48 weeks that group lost about 22.5% more weight than placebo, and nearly half lost at least 20% of their weight. The curve had not flattened by the end.

    The science

    CT388-103 at 24 mg, week 48: placebo-adjusted −22.5% (efficacy estimand) and −18.3% (treatment-regimen estimand), both p < 0.001; 95.7% reached ≥5% loss, 87% ≥10%, 47.8% ≥20% and 26.1% ≥30%; 54% reached a BMI under 30 vs 13% on placebo; 73% of those with prediabetes returned to normal glucose (Roche, Jan-27-2026). Topline and poster; not yet a paper.

    Sources
    • Roche (phase 2 obesity release) (2026)

    Updated Nov 2026

  3. Day 337+Clinical

    A long-term medicine, not a course

    Worth knowing before you stop: with GLP-1 drugs, coming off usually means regaining most of the loss within about a year and a half. Enicepatide hasn't been tested in a stopping trial, so this is the pattern of other weight drugs. Continue, taper or stop is a call for you and your clinician.

    The science

    A BMJ meta-analysis found that after stopping semaglutide or tirzepatide, about 9.9 kg came back within the first year, with weight projected back to baseline about 1.5 years after stopping (West 2026). No withdrawal trial of enicepatide has been published.

    Sources
    • West et al. (2026)

    Updated Nov 2026

Day 1 is the day you start it.

Phase 1 (Chakravarthy 2026, Mol Metab; NCT04838405), obesity phase 2 (Roche, Jan-27-2026; ADA 2026 poster; NCT06525935), diabetes phase 2 (Roche, Sep-22-2026; NCT06628362), ENITH records on ClinicalTrials.gov. Investigational.

Moderate evidence

Mixing and a typical run.

Example numbers

Reconstitution example

Reconstitute a 10 mg vial of Enicepatide with 2 mL of bacteriostatic water and a 2 mg dose is 40 units on a U-100 syringe, about 5 doses per vial.

Vial
10 mg
Water
2 mL
Amount
2 mg

Draw to40 units

0.5 mL insulin syringe · 50 units

Mix it in the Reconstitution LabOpen the calculator

Run notes

Cycle
Used continuously, once weekly, in its trials: 48 weeks in both phase 2 trials, with the dose stepped up over as long as 27 weeks. No trial has tested stopping it.Community practice — opinions vary. Not a clinical recommendation.
Timing
Once weekly SubQ, same day each week, in its trials. In the obesity phase 2, the higher-dose groups stepped up from 2 mg through 4, 8, 12, 16 and 20 mg to 24 mg, reaching their top dose within 27 weeks, with slower steps allowed for tolerability; the lowest groups started at 4 mg. These are trial schedules, not an approved regimen.
Route
SubQ injection
Stacks
BPC-157 (GI support)

Track it in the app

Safety.

Common side effects

  • Nausea
  • Constipation
  • Diarrhea
  • Vomiting

Interactions

No interaction studies have been published. GLP-1 drugs slow stomach emptying, which can change how oral medicines are absorbed. It is a GLP-1 drug itself, so it is not stacked with another one. Roche plans to test it with its amylin drug petrelintide. With insulin or a sulfonylurea, discuss glucose monitoring with your clinician.

Safety notes

Enicepatide has no label: it is still in trials. In the 48-week obesity phase 2 trial, most side effects were GI (nausea, constipation, diarrhea, vomiting) and mild to moderate, in line with the incretin class; 5.9% on enicepatide stopped for side effects vs 1.3% on placebo, and serious events were low and not dose-related, with no grade 4 or 5 events. In the diabetes phase 2 trial, 2.0% stopped for side effects vs 0% on placebo. It is a GLP-1 drug, so the class warnings in GLP-1 labels (including pancreatitis, gallbladder disease and the rodent thyroid C-cell finding) are the ones to read. These are trial findings to review with your clinician.

Mixing charts by vial size.

Questions people ask.

What is Enicepatide?

A weekly GLP-1 and GIP dual agonist from Roche, the same two receptors as tirzepatide, built to keep the receptors responsive by avoiding one of their shut-off signals. In its 48-week obesity phase 2 trial, the top 24 mg dose took off about 22.5% more weight than placebo, and the curve had not flattened.

How is Enicepatide dosed in research?

The research range for Enicepatide is 4–24 mg, weekly, with a 2 mg starting dose. Studied in research — not a recommendation.

How long does Enicepatide last?

The half-life of Enicepatide is ~5.5 days (measured in people: mean 123–139 hours after single doses; phase 1, Chakravarthy 2026).

What do people report on Enicepatide?

Commonly reported on Enicepatide: in trials, GI side effects, mostly mild to moderate, during the step-ups. It is in phase 3 and not approved anywhere.

Is Enicepatide safe?

The research basis for Enicepatide is moderate: animal studies + some human data. Common side effects in the library: nausea, constipation, diarrhea and vomiting.

What does Enicepatide stack with?

Common stacks for Enicepatide: BPC-157 (GI support).

Track it in the app

Research.

The literature

Search the latest research

Reference.

Cadence

Weekly

Half-life

~5.5 days

~5.5 days (measured in people: mean 123–139 hours after single doses; phase 1, Chakravarthy 2026)

Research basis

●●● Moderate

Animal studies + some human data

PepVault for iPhone

Track enicepatide in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo

Reviewed How we check the library